Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CTXR
DateTimeSourceHeadlineSymbolCompany
29/05/202413:30PR Newswire (US)Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionNASDAQ:CTXRCitius Pharmaceuticals Inc
21/05/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
21/05/202412:00PR Newswire (US)Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionNASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202421:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202421:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202421:05PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
10/05/202413:30PR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
30/04/202421:05PR Newswire (US)Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
26/04/202413:00PR Newswire (US)Citius Pharmaceuticals Announces $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
11/04/202413:30PR Newswire (US)Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
04/04/202413:30PR Newswire (US)Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor ConferenceNASDAQ:CTXRCitius Pharmaceuticals Inc
18/03/202412:30PR Newswire (US)Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIRâ„¢ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
07/03/202413:30PR Newswire (US)Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramNASDAQ:CTXRCitius Pharmaceuticals Inc
04/03/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CTXRCitius Pharmaceuticals Inc
26/02/202412:30PR Newswire (US)Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationNASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202421:23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202421:18Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202413:30PR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
15/02/202413:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202421:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202421:30PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202414:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202413:01PR Newswire (US)Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIRâ„¢ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202421:15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202421:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202421:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CTXRCitius Pharmaceuticals Inc
23/01/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
23/01/202413:30PR Newswire (US)Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of DirectorsNASDAQ:CTXRCitius Pharmaceuticals Inc
05/01/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
02/01/202421:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CTXR